Search Results

You are looking at 1 - 10 of 13 items for :

  • "nucleoside analogs" x
  • Refine by Access: All x
Clear All
Full access

Narendranath Epperla, Melissa Pavilack, Temitope Olufade, Richa Bashyal, Teng Huang, Huseyin Yuce, and Leslie Andritsos

Background: Purine nucleoside analogs (PNAs) are highly effective for first-line treatment of hairy cell leukemia (HCL). In clinical trials of single PNAs, several adverse events (AEs) were reported; however, little is known regarding the costs and

Full access

Maria R. Baer and Ivana Gojo

Sapacitabine is a rationally designed, orally administered nucleoside analog that produced a 28% complete remission rate in a phase I trial that included older patients with untreated AML, 26 and is undergoing further testing in this group. Novel

Full access

Jorge Cortes and Francis Giles

; 56 : 4187 – 4191 . 4 Giles FJ Cortes JE Baker SD . Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia . J Clin Oncol 2001 ; 19 : 762 – 771 . 5 Giles FJ Garcia-Manero G Cortes

Full access

Kenneth C. Anderson, Melissa Alsina, William Bensinger, J. Sybil Biermann, Adam D. Cohen, Steven Devine, Benjamin Djulbegovic, Edward A. Faber Jr, Christine Gasparetto, Francisco Hernandez-Ilizaliturri, Carol Ann Huff, Adetola Kassim, Amrita Y. Krishnan, Bruno C. Medeiros, Ruby Meredith, Noopur Raje, Jeffrey Schriber, Seema Singhal, George Somlo, Keith Stockerl-Goldstein, Steven P. Treon, Guido Tricot, Donna M. Weber, Joachim Yahalom, Furhan Yunus, Rashmi Kumar, and Dorothy A. Shead

hyperviscosity; neuropathy; symptomatic adenopathy or organomegaly; amyloidosis; cryoglobulinemia; cold agglutinin disease; and presence of cytopenia. 6 , 7 The primary treatment options for WM/LPL include oral alkylators (eg, chlorambucil), nucleoside analogs

Full access

William G. Wierda, John C. Byrd, Jeremy S. Abramson, Syed F. Bilgrami, Greg Bociek, Danielle Brander, Jennifer Brown, Asher A. Chanan-Khan, Julio C. Chavez, Steve E. Coutre, Randall S. Davis, Christopher D. Fletcher, Brian Hill, Brad S. Kahl, Manali Kamdar, Lawrence D. Kaplan, Nadia Khan, Thomas J. Kipps, Shuo Ma, Sami Malek, Anthony Mato, Claudio Mosse, Vishala T. Neppalli, Mazyar Shadman, Tanya Siddiqi, Deborah Stephens, Nina Wagner, Mary A. Dwyer, and Hema Sundar

patients treated with a combination of purine nucleoside analogs and alkylating agents. 9 Richter's transformation has also been reported after treatment with the novel agents ibrutinib and venetoclax. 15 – 17 Unlike progressive CLL, Richter

Full access

Mikkael A. Sekeres

A . Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenstrom macroglobulinemia treated with nucleoside analogs . J Clin Oncol 2009 ; 27 : 250 – 255 . 26. Josting A Wiedenmann S Franklin J

Full access

Cesar A. Santa-Maria and Rita Nanda

“priming” tumors for immunotherapy. 5-azacitidine is a pyrimidine nucleoside analog that inhibits DNA methyltransferase, resulting in hypomethylation in a number of genes, and can thus regulate gene expression. In vitro studies in breast cancer cell lines

Full access

Patrick Brown, Hiroto Inaba, Colleen Annesley, Jill Beck, Susan Colace, Mari Dallas, Kenneth DeSantes, Kara Kelly, Carrie Kitko, Norman Lacayo, Nicole Larrier, Luke Maese, Kris Mahadeo, Ronica Nanda, Valentina Nardi, Vilmarie Rodriguez, Jenna Rossoff, Laura Schuettpelz, Lewis Silverman, Jessica Sun, Weili Sun, David Teachey, Victor Wong, Gregory Yanik, Alyse Johnson-Chilla, and Ndiya Ogba

(PPIs) can affect the bioavailability of some TKIs. In Ph-like ALL cases harboring CRLF2 and JAK alterations, the utility of Janus kinases inhibitors are being explored. 131 The purine nucleoside analog nelarabine has been approved for the treatment

Full access

Joseph C. Alvarnas, Patrick A. Brown, Patricia Aoun, Karen Kuhn Ballen, Stefan K. Barta, Uma Borate, Michael W. Boyer, Patrick W. Burke, Ryan Cassaday, Januario E. Castro, Peter F. Coccia, Steven E. Coutre, Lloyd E. Damon, Daniel J. DeAngelo, Dan Douer, Olga Frankfurt, John P. Greer, Robert A. Johnson, Hagop M. Kantarjian, Rebecca B. Klisovic, Gary Kupfer, Mark Litzow, Arthur Liu, Arati V. Rao, Bijal Shah, Geoffrey L. Uy, Eunice S. Wang, Andrew D. Zelenetz, Kristina Gregory, and Courtney Smith

remains a challenge. Clofarabine is a nucleoside analog approved for the treatment of pediatric patients (aged 1–21 years) with ALL that is relapsed or refractory after at least 2 prior regimens. 105 In a phase II study of single-agent clofarabine in

Full access

Patrick A. Brown, Bijal Shah, Anjali Advani, Patricia Aoun, Michael W. Boyer, Patrick W. Burke, Daniel J. DeAngelo, Shira Dinner, Amir T. Fathi, Jordan Gauthier, Nitin Jain, Suzanne Kirby, Michaela Liedtke, Mark Litzow, Aaron Logan, Selina Luger, Lori J. Maness, Stephanie Massaro, Ryan J. Mattison, William May, Olalekan Oluwole, Jae Park, Amanda Przespolewski, Sravanti Rangaraju, Jeffrey E. Rubnitz, Geoffrey L. Uy, Madhuri Vusirikala, Matthew Wieduwilt, Beth Lynn, Ryan A. Berardi, Deborah A. Freedman-Cass, and Mallory Campbell

the cornerstone of CRS and ICANS management. Expert consensus clinical guidelines were recently published by the Society of Immunotherapy of Cancer to guide toxicity management. 206 Nelarabine Nelarabine is a nucleoside analog that is currently